HK Stock Market Move | INNOCARE (09969) rose nearly 4% as the company released phase II clinical data for the new BTK inhibitor, Acalabrutinib, on a forum.

INNOCARE (09969) rose nearly 4%, with a cumulative increase of over 60% in the past ten trading days. As of press time, it rose 3.91% to 9.31 Hong Kong dollars with a trading volume of 169 million Hong Kong dollars. On the news front, on February 26th, INNOCARE announced that the company would present the Phase II clinical data of the new BTK inhibitor obutinib for the treatment of relapsing-remitting multiple sclerosis (RRMS) at the 10th Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Forum in 2025. Live poster presentation (Poster Code: P094) is scheduled for February 27th Eastern Time. The research results show that obutinib has demonstrated high efficacy in treating RRMS patients. A once-daily dose of 80 mg of obutinib showed the best efficacy and safety, and will therefore be used as the dose for the Phase III clinical trial of obutinib for the treatment of progressive multiple sclerosis (PMS).